Premotor Parkinson's disease: Clinical features and detection strategies
Identifieur interne : 002123 ( Main/Exploration ); précédent : 002122; suivant : 002124Premotor Parkinson's disease: Clinical features and detection strategies
Auteurs : Randolph Stephenson [États-Unis] ; Andrew Siderowf [États-Unis] ; Matthew B. Stern [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Genetic Techniques, Humans, Medical screening, Molecular imaging, Nervous system diseases, Olfaction, Parkinson Disease (classification), Parkinson Disease (diagnosis), Parkinson Disease (genetics), Parkinson Disease (pathology), Parkinson Disease (radionuclide imaging), Parkinson Disease (ultrasonography), Parkinson disease, Parkinson's disease, Positron-Emission Tomography, Strategy, Ultrasonics, early detection, molecular imaging, olfaction.
- MESH :
- classification : Parkinson Disease.
- diagnosis : Parkinson Disease.
- genetics : Parkinson Disease.
- pathology : Parkinson Disease.
- radionuclide imaging : Parkinson Disease.
- ultrasonography : Parkinson Disease.
- Genetic Techniques, Humans, Positron-Emission Tomography, Ultrasonics.
Abstract
In many areas of medicine, the focus has shifted from treating existing disease to screening and prevention. The technology to screen for Parkinson's disease (PD) already exists. The current challenge is to define the appropriate use of predictive testing for PD. Imaging technologies currently offer the highest degree of accuracy for identifying premotor PD, but they are expensive as screening tools. Efficiency is greatly enhanced by combining imaging with a prescreening test, such as olfactory testing. This two‐step process has the potential to greatly reduce costs while retaining diagnostic accuracy. Ultimately, the role of preclinical detection of PD will be determined by the ability of emerging therapies to influence clinical outcomes. As such, implementation of large‐scale screening strategies awaits the arrival of clearly safe and effective therapies that address the underlying pathogenesis of PD. Current research to evaluate efficient screening methods and to understand the clinical and physiological features of “premotor” PD will lay the foundation for the screening and prevention strategies of the future. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22403
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001940
- to stream Istex, to step Curation: 001940
- to stream Istex, to step Checkpoint: 000D25
- to stream PubMed, to step Corpus: 001B12
- to stream PubMed, to step Curation: 001B12
- to stream PubMed, to step Checkpoint: 001C30
- to stream Ncbi, to step Merge: 002871
- to stream Ncbi, to step Curation: 002871
- to stream Ncbi, to step Checkpoint: 002871
- to stream Main, to step Merge: 002984
- to stream PascalFrancis, to step Corpus: 000C75
- to stream PascalFrancis, to step Curation: 002044
- to stream PascalFrancis, to step Checkpoint: 000D44
- to stream Main, to step Merge: 002E41
- to stream Main, to step Curation: 002123
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Premotor Parkinson's disease: Clinical features and detection strategies</title><author><name sortKey="Stephenson, Randolph" sort="Stephenson, Randolph" uniqKey="Stephenson R" first="Randolph" last="Stephenson">Randolph Stephenson</name></author><author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name></author><author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:141DD21F01715158AAD18211B08868B39420FAEB</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22403</idno><idno type="url">https://api.istex.fr/document/141DD21F01715158AAD18211B08868B39420FAEB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001940</idno><idno type="wicri:Area/Istex/Curation">001940</idno><idno type="wicri:Area/Istex/Checkpoint">000D25</idno><idno type="wicri:doubleKey">0885-3185:2009:Stephenson R:premotor:parkinson:s</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19877244</idno><idno type="wicri:Area/PubMed/Corpus">001B12</idno><idno type="wicri:Area/PubMed/Curation">001B12</idno><idno type="wicri:Area/PubMed/Checkpoint">001C30</idno><idno type="wicri:Area/Ncbi/Merge">002871</idno><idno type="wicri:Area/Ncbi/Curation">002871</idno><idno type="wicri:Area/Ncbi/Checkpoint">002871</idno><idno type="wicri:Area/Main/Merge">002984</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:10-0038136</idno><idno type="wicri:Area/PascalFrancis/Corpus">000C75</idno><idno type="wicri:Area/PascalFrancis/Curation">002044</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000D44</idno><idno type="wicri:doubleKey">0885-3185:2009:Stephenson R:premotor:parkinson:s</idno><idno type="wicri:Area/Main/Merge">002E41</idno><idno type="wicri:Area/Main/Curation">002123</idno><idno type="wicri:Area/Main/Exploration">002123</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Premotor Parkinson's disease: Clinical features and detection strategies</title><author><name sortKey="Stephenson, Randolph" sort="Stephenson, Randolph" uniqKey="Stephenson R" first="Randolph" last="Stephenson">Randolph Stephenson</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennysylvania</wicri:regionArea><wicri:noRegion>Pennysylvania</wicri:noRegion></affiliation></author><author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennysylvania</wicri:regionArea><wicri:noRegion>Pennysylvania</wicri:noRegion></affiliation></author><author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennysylvania</wicri:regionArea><wicri:noRegion>Pennysylvania</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009">2009</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S665">S665</biblScope><biblScope unit="page" to="S670">S670</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">141DD21F01715158AAD18211B08868B39420FAEB</idno><idno type="DOI">10.1002/mds.22403</idno><idno type="ArticleID">MDS22403</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Genetic Techniques</term><term>Humans</term><term>Medical screening</term><term>Molecular imaging</term><term>Nervous system diseases</term><term>Olfaction</term><term>Parkinson Disease (classification)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinson Disease (ultrasonography)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Positron-Emission Tomography</term><term>Strategy</term><term>Ultrasonics</term><term>early detection</term><term>molecular imaging</term><term>olfaction</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="ultrasonography" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Genetic Techniques</term><term>Humans</term><term>Positron-Emission Tomography</term><term>Ultrasonics</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dépistage</term><term>Imagerie moléculaire</term><term>Maladie de Parkinson</term><term>Olfaction</term><term>Pathologie du système nerveux</term><term>Stratégie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In many areas of medicine, the focus has shifted from treating existing disease to screening and prevention. The technology to screen for Parkinson's disease (PD) already exists. The current challenge is to define the appropriate use of predictive testing for PD. Imaging technologies currently offer the highest degree of accuracy for identifying premotor PD, but they are expensive as screening tools. Efficiency is greatly enhanced by combining imaging with a prescreening test, such as olfactory testing. This two‐step process has the potential to greatly reduce costs while retaining diagnostic accuracy. Ultimately, the role of preclinical detection of PD will be determined by the ability of emerging therapies to influence clinical outcomes. As such, implementation of large‐scale screening strategies awaits the arrival of clearly safe and effective therapies that address the underlying pathogenesis of PD. Current research to evaluate efficient screening methods and to understand the clinical and physiological features of “premotor” PD will lay the foundation for the screening and prevention strategies of the future. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Stephenson, Randolph" sort="Stephenson, Randolph" uniqKey="Stephenson R" first="Randolph" last="Stephenson">Randolph Stephenson</name></noRegion><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002123 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002123 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:141DD21F01715158AAD18211B08868B39420FAEB
|texte= Premotor Parkinson's disease: Clinical features and detection strategies
}}
| This area was generated with Dilib version V0.6.23. |  |